{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:13:06Z","timestamp":1789733586823,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of the present study was to determine if the use of the anti\u2010tumor necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>)\u2010\u03b1 monoclonal antibody adalimumab could improve endothelial function and arterial stiffness in patients with moderate to severe psoriasis. This was a prospective study on a series of consecutive patients with moderate to severe psoriasis who completed 6 months of therapy with adalimumab. Patients with history of cardiovascular events, diabetes mellitus, kidney disease, hypertension or body mass index of 35 kg\/m<jats:sup>2<\/jats:sup> or more were excluded. Assessment of endothelial function by brachial artery reactivity measuring flow\u2010mediated endothelial dependent vasodilatation (<jats:styled-content style=\"fixed-case\">FMD<\/jats:styled-content>%), and carotid arterial stiffness by pulse wave velocity (<jats:styled-content style=\"fixed-case\">PWV<\/jats:styled-content>) was performed at the onset of treatment (time 0) and at month 6. Twenty\u2010nine patients were studied. Anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 adalimumab therapy yielded a significant improvement of endothelial function. The mean \u00b1 standard deviation (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">FMD<\/jats:styled-content>% values increased from 6.19 \u00b1 2.44% at the onset of adalimumab to 7.46 \u00b1 2.43% after 6 months of treatment with this biologic agent (<jats:italic>P<\/jats:italic> = 0.008). Likewise, following the use of adalimumab, <jats:styled-content style=\"fixed-case\">PWV<\/jats:styled-content> levels decreased from 6.28 \u00b1 1.04 m\/s at the onset of adalimumab to 5.69 \u00b1 1.31 m\/s at 6 months (<jats:italic>P<\/jats:italic> = 0.03). In conclusion, patients with moderate to severe psoriasis exhibit improvement of endothelial function and arterial stiffness following anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 therapy. These findings are of potential relevance due to increased risk of cardiovascular disease in patients with severe psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.13398","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T17:43:19Z","timestamp":1460310199000},"page":"1267-1272","source":"Crossref","is-referenced-by-count":57,"title":["Anti\u2010tumor necrosis factor\u2010alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6\u2010month prospective study"],"prefix":"10.1111","volume":"43","author":[{"given":"Trinitario","family":"Pina","sequence":"first","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Corrales","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lopez\u2010Mejias","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Armesto","sequence":"additional","affiliation":[{"name":"Dermatology Division IDIVAL Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos A.","family":"Gonzalez\u2010Lopez","sequence":"additional","affiliation":[{"name":"Dermatology Division IDIVAL Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"G\u00f3mez\u2010Acebo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Computational Biology School of Medicine IDIVAL University of Cantabria and CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Ubilla","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Remuzgo\u2010Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carmen","family":"Gonzalez\u2010Vela","sequence":"additional","affiliation":[{"name":"Pathology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IDIVAL Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[{"name":"Dermatology Division IDIVAL Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonzalez\u2010Gay","sequence":"additional","affiliation":[{"name":"Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases Rheumatology Division Hospital Universitario Marqu\u00e9s de Valdecilla University of Cantabria Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1493"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.94"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02936.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200502000-00001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08190.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0703-z"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.370"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.16"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10031.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22530"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1684\/ejd.2011.1324","article-title":"Endothelial dysfunction in psoriasis patients: Cross\u2010sectional case\u2010control study","volume":"21","author":"Simone C","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-013-0387-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10107.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12814"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13005"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-88"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-39"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.03.028"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.020"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.02.001"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03481.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22884"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket454"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.019"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.01.012"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003319713485805"},{"key":"e_1_2_7_30_1","first-page":"309","article-title":"Short\u2010term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab","volume":"24","author":"Gonzalez\u2010Juanatey C","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/674265"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.12.093"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13398","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:56:52Z","timestamp":1695571012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/1346-8138.13398"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13398","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]}}}